Afficher la notice abrégée

dc.contributor.authorHua, T.D.fr_FR
dc.contributor.authorFulcrand-Rolland, V.fr_FR
dc.contributor.authorLefranc, M.P.fr_FR
dc.contributor.authorWeill, M.fr_FR
dc.date.accessioned2013-02-15T12:00:34Z
dc.date.available2013-02-15T12:00:34Z
dc.date.issued1994fr_FR
dc.identifier.citationHua, T.D. ; Fulcrand-Rolland, V. ; Lefranc, M.P. ; Weill, M., Anticorps catalytiques, Med Sci (Paris), 1994, Vol. 10, N° 6-7; p.672-8fr_FR
dc.identifier.issn1958-5381fr_FR
dc.identifier.urihttp://hdl.handle.net/10608/2684
dc.description.abstractIn 1946, Linus Pauling argued that an enzyme derives its catalytic power by binding the transition state of a reaction more tightly than either its substrates or products. Thus, the active site of an enzyme lowers the energy barrier of the reaction and thereby increases the reaction rate. In 1969, Jencks suggested that an antibody, raised against a stable transition state analog of a reaction, should act as a potent catalyst. Since 1986, the vast repertoire of the immune system has been exploited for the generation of tailor-made biological catalysts. A number of strategies have been developed to generate catalytic antibodies that carry out a wide range of reactions with exquisite specificities.fr
dc.language.isofrfr_FR
dc.publisherJohn Libbey Eurotext, Montrougefr_FR
dc.rightsArticle en libre accèsfr
dc.rightsMédecine/Sciences - Inserm - SRMSfr
dc.sourceM/S. Médecine sciences [revue papier, ISSN : 0767-0974], 1994, Vol. 10, N° 6-7; p.672-8fr_FR
dc.titleAnticorps catalytiquesfr
dc.typeArticlefr_FR
dc.identifier.doi10.4267/10608/2684


Fichier(s) constituant ce document

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée